DUBLIN – The FDA's surprise rejection of Amgen Inc.'s application for approval of Parsabiv (etelcalcetide) in secondary hyperparathyroidism (SHPT) is now looking even more curious, as the same drug is set to gain approval in Europe.
DUBLIN – Eyevensys SAS extended its series A funding round with an injection of €1.5 million (US$ 1.7 million) from Pontifax Venture Capital, taking the total raise to €9 million. The Paris-based company is pioneering gene delivery to the eye using electroporation or, in its own parlance, “electro-transfection.”
DUBLIN – AC Immune SA is seeking up to $59 million in a Nasdaq IPO to help fund its broad portfolio of therapeutics and diagnostics in development for neurodegenerative and central nervous system (CNS) disorders.
DUBLIN – Newly formed startup Inflazome Ltd. has secured up to $17 million in series A funding to take forward a series of small-molecule inhibitors of the NLRP3 inflammasome, which is implicated in a wide range of chronic conditions with an underlying inflammatory component.
DUBLIN – A syndicate of European venture capital investors has followed its own money in a sizable third closing of Rigontec GmbH's series A round, adding €15 million (US$16.7 million) in new cash, which takes the final tally to €29.25 million.
DUBLIN – DBV Technologies SA is extending its patch-based antigen delivery technology, which is currently undergoing a pivotal phase III trial in a food allergy indication, into its first vaccine study.
DUBLIN – The evaporation of political support in Europe for the Transatlantic Trade and Investment Partnership (TTIP), a comprehensive U.S.-EU free trade deal, was overshadowed this week by the dramatic ruling from the European Commission's (EC) Competition Directorate General (DG Competition).
DUBLIN – Shares in Saniona AB gained 25 percent Monday on news of an ion channel drug discovery pact in schizophrenia with Boehringer Ingelheim GmbH worth up to €90 million (US$101 million) in up-front and milestone payments.
DUBLIN – Astrazeneca plc's small-molecule antibiotics business is hardly the jewel in its crown, but more than two years after Pfizer Inc.'s $116 billion cash-and-shares bid for the whole company ran into the ground, it is putting down $725 million and could pay up to $850 million more to gain ex-U.S. rights to an anti-infectives portfolio of three marketed and two development-stage assets.
